> Three health information companies are suing the states of Vermont and Maine to block laws that would prevent drug makers from tracking individual scrips written by individual doctors; the privacy laws are set to take effect January 1. Release [1]
> Watson Pharmaceuticals has asked the FDA to approve its copycat of Femcon, a Warner Chilcott birth-control pill; Warner Chilcott, meanwhile, sued the generics maker to block the drug. Release [2]
> Contract manufacturer SAFC says it's planning to add conjugation capabilities to its Missouri plant, aiming to target pharma clients developing novel anti-cancer drugs. Report [3]
> The troubled PDL BioPharma has put out the 'for sale' sign in an attempt to find a buyer for the company as a whole or of its key assets. Report [4]
> Perlegen Sciences and Roche's [5] 454 Life Sciences have teamed up to conduct large scale genetic re-sequencing in DNA samples collected from people with specific responses to an undisclosed class of drug. Report [6]
And Finally... Antibiotics might fight stroke, too: A small new study showed that minocycline administered within 24 hours of a stroke reduced brain damage and physical impairment. Report [7]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-ims-health-wolters-kluwer-health-and-verispan-challenge-state-laws-0
[2] http://www.fiercebiotech.com/press-releases/press-release-watson-files-application-generic-femcon-femcon
[3] http://www.outsourcing-pharma.com/news/ng.asp?n=80281-safc-drug-conjugates-high-potency-apis
[4] http://www.fiercebiotech.com/story/pdl-biopharma-puts-out-sale-sign/2007-10-02
[5] http://www.fiercebiotech.com/story/roche-snares-454-s-sequencing-tech-in-buyout/2007-03-29
[6] http://www.fiercebiotech.com/story/perlegen-454-study-drug-response/2007-10-02
[7] http://www.latimes.com/features/health/la-sci-stroke2oct02,1,7048247.story?coll=la-headlines-health